Thalidomide therapy in adult patients with myelodysplastic syndrome: A north central cancer treatment group phase II trial [1]

Cancer

Volumn 109, Issue 6, 2007, Pages 1211-1212

  Musto, Pellegrino ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADVANCED CANCER; BLOOD TRANSFUSION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG TOLERABILITY; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33947269813     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22516     Document Type: Letter

References (5)

1. Moreno-Aspitia A, Colon-Otero G, Hoering A, et al. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer. 2006;107:767-772.
2. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1-6.
3. Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87:884-886.
4. Bouscary D, Legros L, Tulliez M, et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol. 2005;131:609-618.
5. Bowen D, MacIlwaine L, Cavanagh J, et al. Thalidomide therapy for low-risk myelodysplasia. Leuk Res. 2005;29:235-236.